Just 20% of firms with 200 or more workers said they covered GLP-1 drugs for weight loss, according to the Peterson-KFF Health System Tracker.
Our daily email brings you smart and engaging news and analysis on the biggest stories in business and finance. For free.
Science Corp., a brain-implant startup developing a device that can enable blind people to see again, just raised $230 million from investors.
Oil production in the Middle East may fall dramatically if the Iran conflict traps stockpiles from being shipped out of the region.
The cost of producing gaming consoles on the up, but Sony is doubling down on its PlayStation 5 and reportedly pulling titles away from PCs.
Shares in stagnant retailer Target surged as executives pitched investors on a turnaround plan that includes $5 billion in capital spending.
Oil prices are surging as Iran’s counterattacks on the US and Israel curbed shipments through the Strait of Hormuz.
Berkshire stock, which has lagged the S&P 500 for the past 12 months, fell Monday as results from Warren Buffett’s last quarter underwhelmed.
ChatGPT users are ghosting the OpenAI chatbot and sliding into the DM’s of Anthropic’s Claude after CEO Sam Altman’s Pentagon deal.
As the GLP-1 drugs like Wegovy and Zepbound have proven, there’s a lot of money to be made in helping people look good and feel good.
Beleagured Boeing won more plane orders in 2025 than rival Airbus for the first time in seven years but faces an uphill battle in deliveries.
Smucker is under pressure to sweeten its sales from activist Elliott Investment Management, now one of the company’s biggest stakeholders.
Netflix, with its 325 million subscribers, swears its potential (if not likely) acquisition of Warner Bros amounts to vertical integration.
Wall Street’s latest obsession with asset-heavy stocks are buoying the home improvement company’s fortunes on Wall Street.
Anthropic is insisting that its AI shouldn’t be used for surveillance or the development of automated weapons.
The pharma giant already held an 11.5% stake as part of a 2022 effort to co-develop and co-commercialize the cancer treatment anito-cel.